bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S7 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

A. PCA of protein expression profiles of WM3965 control and progression tumor grafts. B. unsupervised hierarchical clustering of proteins identified in the PCA.
Supplemental Table 3 from Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Authors: de Leeuw Renée , Berman-Booty Lisa D. , Schiewer Matthew J. , Ciment Stephen J. , Den Robert B. , Dicker Adam P. , Kelly William K. , Trabulsi Edouard J. , Lallas Costas D. , Gomella Leonard G. , Knudsen Karen E.
Published: April 2023

GO pathway analyses per gene cluster in Figure 6A - LNCaP and C4-2.
Supplementary figure legends from Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Authors: Chong Curtis R. , Bahcall Magda , Capelletti Marzia , Kosaka Takayuki , Ercan Dalia , Sim Taebo , Sholl Lynette M. , Nishino Mizuki , Johnson Bruce E. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Legends to the supplementary figures
Supplemental Figure 1 from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer
Authors: Ferrarotto Renata , Goonatilake Ruchitha , Young Yoo Suk , Tong Pan , Giri Uma , Peng Shaohua , Minna John , Girard Luc , Wang Yuehong , Wang Liguang , Li Lerong , Diao Lixia , Peng David H. , Gibbons Don L. , Glisson Bonnie S. , Heymach John V. , Wang Jing , Byers Lauren A. , Johnson Faye M.
Published: April 2023

Treatment with GSK461364 induced ABCB1 and ABCC1 expression in NSCLC cells at high concentrations. NSCLC cell lines were incubated with dimethyl sulfoxide (vehicle control) or volasertib for 2 hours at the indicated concentrations. Cells were then lysed and subjected to Western blotting with the indicated primary antibodies.
Supplemental Figure S4 from Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
Authors: Brooks Samira A. , Khandani Amir H. , Fielding Julia R. , Lin Weili , Sills Tiffany , Lee Yueh , Arreola Alexandra , Milowsky Mathew I. , Wallen Eric M. , Woods Michael E. , Smith Angie B. , Nielsen Mathew E. , Parker Joel S. , Lalush David S. , Rathmell W. Kimryn
Published: April 2023

HIF2 expression in ccA and ccB-typed samples.
Supplementary Information from Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Authors: Shor Boris , Kahler Jennifer , Dougher Maureen , Xu Jane , Mack Michelle , Rosfjord Ed , Wang Fang , Melamud Eugene , Sapra Puja
Published: April 2023

Supplementary Methods to complete the information for cellular assays in vitro and protein identification by mass spectrometry. The file also contains legends for supplementary figures S1-S6 and supplementary tables S1-S3.
High Resolution Supplementary Fig.S5A from Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Authors: Shor Boris , Kahler Jennifer , Dougher Maureen , Xu Jane , Mack Michelle , Rosfjord Ed , Wang Fang , Melamud Eugene , Sapra Puja
Published: April 2023

High resolution image for Supplementary Fig.S5A.
Supplementary 4 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Authors: Yu Shang-Fan , Zheng Bing , Go MaryAnn , Lau Jeff , Spencer Susan , Raab Helga , Soriano Robert , Jhunjhunwala Suchit , Cohen Robert , Caruso Michele , Polakis Paul , Flygare John , Polson Andrew G.
Published: April 2023

Supplementary 4. P-gp overexpressing BJAB.Luc cell line showed the similar resistance to anti-CD22-vc-MMAE
supplemental figure legend from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
Authors: Arai Sally , Pidala Joseph , Pusic Iskra , Chai Xiaoyu , Jaglowski Samantha , Khera Nandita , Palmer Jeanne , Chen George L. , Jagasia Madan H. , Mayer Sebastian A. , Wood William A. , Green Michael , Hyun Teresa S. , Inamoto Yoshihiro , Storer Barry E. , Miklos David B. , Shulman Howard M. , Martin Paul J. , Sarantopoulos Stefanie , Lee Stephanie J. , Flowers Mary E.D.
Published: April 2023

supplemental figure legend
Supplemental Figure Legend from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
Authors: Galimberti Sara , Luminari Stefano , Ciabatti Elena , Grassi Susanna , Guerrini Francesca , Dondi Alessandra , Marcheselli Luigi , Ladetto Marco , Piccaluga Pier Paolo , Gazzola Anna , Mannu Claudia , Monitillo Luigia , Mantoan Barbara , Del Giudice Ilaria , Della Starza Irene , Cavalli Marzia , Arcaini Luca , Tucci Alessandra , Palumbo Giuseppe Alberto , Rigacci Luigi , Pulsoni Alessandro , Vitolo Umberto , Boccomini Carola , Vallisa Daniele , Bertoldero Giovanni , Gaidano Gianluca , Musto Pellegrino , Petrini Mario , Federico Massimo
Published: April 2023

Supplemental Figure Legend from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
Supplemental Figure 4 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Authors: Song Shumei , Honjo Soichiro , Jin Jiankang , Chang Shih-Shin , Scott Ailing W. , Chen Qiongrong , Kalhor Neda , Correa Arlene M. , Hofstetter Wayne L. , Albarracin Constance T. , Wu Tsung-Teh , Johnson Randy L. , Hung Mien-Chie , Ajani Jaffer A.
Published: April 2023

Supplemental Figure 4. Level of YAP1, EGFR and KI67 in mice tumors was dramatically diminished by the combination treatment of VP and 5-FU
Supplementary Figure 5 from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

Supplementary Figure 5. Survival analysis according to HER2 gene copy number in validation cohort
Supplementary Figure 4 from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

Supplementary Figure 4. Overall survival and objective response rate according to HER2 gene copy number.
Supplementary Methods and Datas from A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria
Authors: Wang Xuefeng , Zhang Chen , Yan Xiangming , Lan Bin , Wang Jianyong , Wei Chongyang , Cao Xingxin , Wang Renxiao , Yao Jianhua , Zhou Tao , Zhou Mi , Liu Qiaoling , Jiang Biao , Jiang Pengfei , Kesari Santosh , Lin Xinjian , Guo Fang
Published: April 2023

This file contains supplementary methods and supplementary figure legends.
Supplementary Datas from A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria
Authors: Wang Xuefeng , Zhang Chen , Yan Xiangming , Lan Bin , Wang Jianyong , Wei Chongyang , Cao Xingxin , Wang Renxiao , Yao Jianhua , Zhou Tao , Zhou Mi , Liu Qiaoling , Jiang Biao , Jiang Pengfei , Kesari Santosh , Lin Xinjian , Guo Fang
Published: April 2023

Supplemental Figure S1. 1H NMR spectrum and 13C spectrum of ch282-5. Supplemental Figure S2. LC/MS Report of ch282-5. Supplemental Figure S3. Synthesis profile of ch282-5 (2-aminoethanesulfonic acid sodium-gossypolone). Supplemental Table S1. The biological prediction of ch282-5. Supplemental Figure S4. Stability of ch282-5 in biological condition. Supplemental Figure S5. Binding affinities to Bcl-2 family proteins. Supplemental Table S2. Cell Viability Assay of ch282-5. Supplemental Figure S6. ch282-5 inhibits colon cancer cell ability. Supplemental Figure S7. ch282-5 regulates Bcl-2 family proteins. Supplemental Figure S8. ch282-5 antitumor ability is augmented by disturbing mitophagy and mTOR pathway. Supplemental Figure S9. ch282-5 suppresses liver colonization of colon cancer cells. Supplemental Figure S10. A schematic diagram of anti-colon cancer effects by ch282-5.
Supplementary Figure2 from Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Authors: Yan Pu , Klingbiel Dirk , Saridaki Zenia , Ceppa Paola , Curto Monica , McKee Thomas Alexander , Roth Arnaud , Tejpar Sabine , Delorenzi Mauro , Bosman Fredrik T. , Fiocca Roberto
Published: April 2023

Kaplan-Meier curves for RFS (A, C) and OS (B, D) of the MSS (A, B) and of the MSI (C, D) patients, respectively by SMAD4 expression status
Supplementary Data from Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy
Authors: Lam Siu W. , Nota Nienke M. , Jager Agnes , Bos Monique M.E.M. , van den Bosch Joan , van der Velden Ankie M.T. , Portielje Johanneke E.A. , Honkoop Aafke H. , van Tinteren Harm , Boven Epie
Published: April 2023

Supplementary Table 1. Clinical outcome of original trial population and biomarker population Supplementary Table 2. Baseline plasma protein levels vs baseline patient and tumor characteristics Supplementary Table 3. Spearman Rho correlation coefficients among protein levels at baseline Supplementary Table 4. Plasma protein changes vs baseline patient and tumor characteristics Supplementary Table 5. Change in levels of proteins per treatment arm Supplementary Table 6. Spearman Rho correlation coefficients among protein changes on C2D1 from baseline Supplementary Figure 1A. A plot of Martingale residual vs log-transformed CA9 change for death Supplementary Figure 1B. Estimation of an optimal cut-off point for CA9 change Supplementary Figure 1C. Changes in CA9 levels in the subgroups of a high rise and a low/no rise
supplementary legend from Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vathipadiekal Vinod , Wang Victoria , Wei Wei , Waldron Levi , Drapkin Ronny , Gillette Michael , Skates Steven , Birrer Michael
Published: April 2023

supplementary table legend
Supplementary Table 2 from Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vathipadiekal Vinod , Wang Victoria , Wei Wei , Waldron Levi , Drapkin Ronny , Gillette Michael , Skates Steven , Birrer Michael
Published: April 2023

Supplementary Table 2. List of pathways identified for the statistically significant up-regulated probesets in cancer as compared to normal fallopian tube.
Supplemental Table 2 from New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
Authors: Kisiel John B. , Raimondo Massimo , Taylor William R. , Yab Tracy C. , Mahoney Douglas W. , Sun Zhifu , Middha Sumit , Baheti Saurabh , Zou Hongzhi , Smyrk Thomas C. , Boardman Lisa A. , Petersen Gloria M. , Ahlquist David A.
Published: April 2023

Supplemental Table 2. Comparison to ICGC array data
Supplemental Figure 7 from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Supplemental figure with results from RNA interference experiment
Supplementary Table S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

Supplementary Table S2: This table provides a list of genes whose expression was increased or decreased in patients who developed early brain metastases compared to patients who did not.
Supplementary Figure S4 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

Effect of astrocytes on PLEKHA5 silencing and cell viability in A375Br cells. Cells were transfected with 40 nmol/L of PLEKHA5 siRNA in conditional medium of astrocytes for 96 h. Cell viability of A375Br cells cultured in the absence or presence astrocytes was similarly inhibited by PLEKHA5 siRNA.
Supplementary Figure S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

PLEKHA5 silencing in A375Br and YUMUL cells at different siRNA concentrations. A375Br and YUMUL cells were transfected with siRNA against PLEKHA5 at three different doses (10 nmol/L, 20 nmol/L and 40 nmol/L) or a nontargeting control siRNA (40 nmol/L) (Control). Knock-down is demonstrated by Western blot.
Supplementary Tables from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

Supplementary Table 1. RT-PCR primers for Wnt16, AKT1 and GAPDH, and primers for Wnt16 and AKT1 3'-UTR in the luciferase report assay Supplementary Table 2. Differentiated dysregulation of miRNAs in T-LBL Supplementary Table 3. The corresponding cutoff score of miR-374b expression for each clinicapathological feature according to ROC curve analysis Supplementary Table 4. Association of miR-374b downregulation with clinicopathological features of 58 L-TBL patients
Supplementary Figure 1 from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

Receiver operation characteristic (ROC) curve analysis was employed to determine the cutoff score for the high expression of miR-374b
Table S4 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

Motif analyses for chromatin binding sites of SRC3-pS543 shared or selectively enriched for ERï�¡ in MCF7 cells.
Table S3 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

Clinico-pathological characteristics of Nottingham Tenovus Primary breast cancer Series
Supplemtary Figures S 1-14 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

S1: Image of full size blot for figure 1A; S2: Image of full size blot for figure 1B; S3: SRC3-pS543 and SRC3 chromatin binding patterns in MCF7 cells; S4: Venn diagram of SRC1, SRC2 and SRC3-pS543 enriched binding sites; S5: A. ChIP-QPCR validation of differential enriched chromatin binding sites for total SRC3 and SRC3-pS543; S6: Hormone dependence and phospho-specificity of SRC3-pS543 at sites either or not shared with total SRC3; S7: Overlap of ERïƒ¡ï€ and SRC3 with other publically available datasets; S8: Fulvestrant decreases SRC3-pS543/chromatin interactions at sites shared with ERïƒ¡; S9: Venn diagram, showing the overlap of GO pathways enriched for genes proximal to chromatin binding sites for SRC3-pS543 unique, SRC3 unique or shared regions; S10: 2D graph of normalized ChIP-seq data, illustrating signal for ERïƒ¡, total SRC3, H3K4me1, H3K4me2, H3K4me3 and H3K27Ac binding events at genomic regions occupied by SRC3-pS543; S11: Histological analysis of SRC3 and SRC3-pS543 expression in representative tumour sections; S12: Scatterplot analysis for total SRC3 versus SRC3-pS543 signal in the Nottingham Tenovus Primary Breast Carcinoma Series; S13: Disease Free Survival and breast cancer specific survival in breast cancer patients based on SRC3 protein expression; S14: Disease Free Survival and breast cancer specific survival in patients with HER2 positive and SRC3 high breast cancers compared with all other patients.
Suppl Figure and table legends from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

Figure and table legends for supplementary data
Supplementary Tables 1-2 from Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study
Authors: Vidal Adriana C. , Howard Lauren E. , Moreira Daniel M. , Castro-Santamaria Ramiro , Andriole Gerald L. , Freedland Stephen J.
Published: April 2023

Supplementary Tables 1-2. Supplementary Table 1. Association between ASA and NSAID use and prostate cancer risk or disease grade vs. non-use stratified by treatment arm Supplementary Table 2. Association between ASA and/or NSAID use and prostate cancer risk or disease grade vs. non-use stratified by treatment arm
Supplementary Table 3 from Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Authors: Parkin Brian , Ouillette Peter , Yildiz Mehmet , Saiya-Cork Kamlai , Shedden Kerby , Malek Sami N.
Published: April 2023

Supplementary Table 3. Catalog of all SNP 6.0 array-based aCNA and cnLOH for MI-AML and TCGA cohorts.
Supplementary Figure 2 from Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Authors: Parkin Brian , Ouillette Peter , Yildiz Mehmet , Saiya-Cork Kamlai , Shedden Kerby , Malek Sami N.
Published: April 2023

Supplementary Figure 2. Univariate analyses of gene mutation status.
supplemental table 2 from Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection
Authors: Moon Pyong-Gon , Lee Jeong-Eun , Cho Young-Eun , Lee Soo Jung , Jung Jin Hyang , Chae Yee Soo , Bae Han-Ik , Kim Young-Bum , Kim In-San , Park Ho Yong , Baek Moon-Chang
Published: April 2023

List of proteins identified EVs derived from the breast cancer cell line MDA-MB-231. For each protein, they show IPI accession number, protein description, Mascot score, and protein mass.
supplemental table 1 from Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection
Authors: Moon Pyong-Gon , Lee Jeong-Eun , Cho Young-Eun , Lee Soo Jung , Jung Jin Hyang , Chae Yee Soo , Bae Han-Ik , Kim Young-Bum , Kim In-San , Park Ho Yong , Baek Moon-Chang
Published: April 2023

List of proteins quantified between control and breast cancer. For each protein, they show IPI accession number, protein description, ratio from each patient, ,average and common protein in MDA-MB-231.
supplemental information from Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection
Authors: Moon Pyong-Gon , Lee Jeong-Eun , Cho Young-Eun , Lee Soo Jung , Jung Jin Hyang , Chae Yee Soo , Bae Han-Ik , Kim Young-Bum , Kim In-San , Park Ho Yong , Baek Moon-Chang
Published: April 2023

Supplemental Figure 1. Study design, including sample collection, discovery, test and validation. Supplemental Figure 2. Characterization of EVs isolated from human plasma and MDA-MB-231 cells. Supplemental Figure 3. Optimization of ELISA. Linearity of ELISA Method 1 (A) and ELISA Method 2 (B) for the quantification of Del-1 on EV in plasma. Supplemental Figure 4. CA 15-3 levels in plasma from patients with BC in test set. The black horizontal lines are means, and error bars are SEs. Healthy controls (HC). Supplemental Figure 5. The relationships among the number of circulating EVs, tumor sizes, and Del-1 or CD63 levels, in patients with breast cancer. Supplemental Figure 6. Correlation between Del-1 levels and the status of four types of receptors associated with BC in the test cohort. Supplemental Figure 7. Del-1 levels in plasma in the validation cohort using two types of ELISA.
Supplementary Figure S1 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Authors: Tanaka Hiroki , Fujiwara Hiroshi , Ochi Fumihiro , Tanimoto Kazushi , Casey Nicholas , Okamoto Sachiko , Mineno Junichi , Kuzushima Kiyotaka , Shiku Hiroshi , Sugiyama Takashi , Barrett A. John , Yasukawa Masaki
Published: April 2023

A lentiviral vector expressing the chimeric cCD16 with a 158V/V-CD3Î¶ receptor gene. (a) cDNA encoding the signal peptide and extracellular domain of CD16 gene (accession no.: NM_000569) with a gene alteration at F158V was connected to the CD3Î¶ gene (accession no.: NM_198053) at the second amino acid (P) of the extracellular domain (modified from which we have previously reported.23). SP: signal peptide of CD16 (53 amino acids); aa158: amino acid at position 158; V: replaced to valine; 1ECD: extracellular domain of CD16 (189 amino acids); 2ECD: extracellular domain of CD3Î¶ (2 amino acids); TM: transmembrane portion of CD3Î¶ (21 amino acids); ICP: intracellular portion of CD3Î¶ï�º(144 amino acids); aa: amino acid. AscI and SalI are restriction enzymes. (b) Using a lentiviral vector, the cCD16Î¶ receptor gene was successfully introduced into HEK293T being negative for CD3. (c) T cells lentivirally gene-modified using cCD16Î¶ receptor gene transfer (cCD16Î¶-T cells) successfully displayed cytocidal activity through recognition of the CCR4-Mog complex on target cells, and not via NK cell activity. cCD16Î¶-T cells successfully killed CCR4-positive MT-4 cells, but not CCR4-negative K562, K562-A24, LCL and Jurkat cells in the presence of 1.0Î¼g/mL Mog. Neither K562 nor K562-A24 were killed by cCD16Î¶-T cells in the presence or absence of Mog, indicating that NK cell activity was not involved in this ADCC activity mediated by cCD16Î¶-T cells. K562-A24, HLA-A*24:02-transduced K562; LCL, EBV-immortalized B cell line; NGM-T, non-gene-modified T cells; both NGM-T and cCD16Î¶-T were generated from the same donor; Mog, mogamulizumab; E/T ratio, effector/target ratio. Each experiment was conducted in triplicate. Error bars depict SD.
Supplemental Figure Legends and Tables 1 and 2 from Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Authors: Huang Pinbo , Zhuang Baoxiong , Zhang Heyun , Yan Haiyan , Xiao Zhiyu , Li Wenbin , Zhang Jianlong , Tang Qibin , Hu Kaishun , Koeffler H. Phillip , Wang Jie , Yin Dong
Published: April 2023

Supplemental Figure Legends and Tables 1 and 2. Supplemental Table 1.Clinical characteristics of HCC patients with or without HBV. Supplemental Table 2. CI of bortezomib and PD98059 in PLC/PRF/5, HepG2-HBx and Huh7-HBx cells.
Supplementary Figure S2 from Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Authors: Hurley Paula J. , Sundi Debasish , Shinder Brian , Simons Brian W. , Hughes Robert M. , Miller Rebecca M. , Benzon Benjamin , Faraj Sheila F. , Netto George J. , Vergara Ismael A. , Erho Nicholas , Davicioni Elai , Karnes R. Jeffrey , Yan Guifang , Ewing Charles , Isaacs Sarah D. , Berman David M. , Rider Jennifer R. , Jordahl Kristina M. , Mucci Lorelei A. , Huang Jessie , An Steven S. , Park Ben H. , Isaacs William B. , Marchionni Luigi , Ross Ashley E. , Schaeffer Edward M.
Published: April 2023

Germline ASPN D-repeat-length is variable among the population.
Supplementary Figure 5 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Overall survival and distribution after first dose of ipilimumab according to subsequent treatments. Of 209 patients, 71 received at least one additional systemic line of treatment after ipilimumab. 137 individuals did not receive further therapy and data were not available for one patient. 47 (combination model 1) or 67 (combination model 2) of 71 patients had complete data for classification according to biomarker combination models. The representation of PD-1/PD-L1-treated patients in the biomarker groups was shifted towards favorable biomarker combination groups for both combination models compared to those without subsequent PD-1/PD-L1 treatment. Therefore, a confounding effect of subsequent treatment with PD-1/PD-L1 antibodies on the biomarker results of this study cannot be ruled out (A). To investigate the potential confounding impact on OS and biomarker findings, subsequent treatments were categorized into three different groups: BRAF/MEK inhibitors (n=24), PD-1/PD-L1 antibodies (n=28), and chemotherapy/other treatments (n=33) and analyzed by the Kaplan-Meier method (B). Patients treated with PD-1/PD-L1 antibodies had a significant better survival compared to all 71 patients (p=0.006), while no significant difference was observed for the other two groups. Kaplan Meier analysis of overall survival of patients classified according to combination model 1 (C) or combination model 2 (D) is presented after exclusion of individuals who received subsequent treatment with anti-PD-1 or PD-L1 antibodies, as a confounding effect could not be ruled out. However, the prognostic impact of the proposed biomarker combinations at baseline of ipilimumab treatment remained strong (p<0.018 for all pairwise comparisons of categories of the respective model). Censoring is indicated by vertical lines. Programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1), Risk score (RS).
Supplementary Figures 1-3 from Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Authors: Kuiatse Isere , Baladandayuthapani Veerabhadran , Lin Heather Y. , Thomas Sheeba K. , Bjorklund Chad C. , Weber Donna M. , Wang Michael , Shah Jatin J. , Zhang Xing-Ding , Jones Richard J. , Ansell Stephen M. , Yang Guang , Treon Steven P. , Orlowski Robert Z.
Published: April 2023

Supplementary Figures 1-3. Supplementary Figure 1. Fostamatinib induces apoptosis in a dose-dependent manner. Supplementary Figure 2. Fostamatinib shows enhanced activity in combination with bendamustine. Supplementary Figure 3. Fostamatinib shows enhanced activity in combination with bendamustine.
Figure S9 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Clinical significance of RRS in validation cohort.
Figure S7 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

dot plots
Table S2 from RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Authors: Hayashi Takuo , Desmeules Patrice , Smith Roger S. , Drilon Alexander , Somwar Romel , Ladanyi Marc
Published: April 2023

The mutation details and clinicopathologic data for 24 patients with concurrent RASA1/NF1 mutations.
Figure S5 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Selection of candidate genes for quantitative reverse transcription (qRT) PCR experiments. GO, Gene Ontology database.
Supplemental legend from RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Authors: Hayashi Takuo , Desmeules Patrice , Smith Roger S. , Drilon Alexander , Somwar Romel , Ladanyi Marc
Published: April 2023

Supplemental legend
Figure S3 from RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Authors: Hayashi Takuo , Desmeules Patrice , Smith Roger S. , Drilon Alexander , Somwar Romel , Ladanyi Marc
Published: April 2023

Survival analysis in lung cancer patients with RASA1 or NF1 mutation or both.
Figure S2 from RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Authors: Hayashi Takuo , Desmeules Patrice , Smith Roger S. , Drilon Alexander , Somwar Romel , Ladanyi Marc
Published: April 2023

Co-administration of trametinib and afatinib induces apoptosis in NSCLC lines with RASA1 mutations.
Supplementary Tables 1-6 from Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Authors: Maréchal Raphaël , Bachet Jean-Baptiste , Calomme Annabelle , Demetter Pieter , Delpero Jean Robert , Svrcek Magali , Cros Jérôme , Bardier-Dupas Armelle , Puleo Francesco , Monges Geneviève , Hammel Pascal , Louvet Christophe , Paye François , Bachelier Philippe , Le Treut Yves Patrice , Vaillant Jean-Christophe , Sauvanet Alain , André Thierry , Salmon Isabelle , Devière Jacques , Emile Jean-François , Van Laethem Jean-Luc
Published: April 2023

Supplementary Tables 1-6. Table 1 shows the correlation between immunohistochemical factors and clinicopathological data, Table 2: Univariate analyses of patients characteristics and IHC factors to disease-free survival, Table 3: Multivariate analysis for training and validation sets: clinicopathological variables, Table 4: Multivariate Analyses: OS for patients according to the nodal status, Table 5: Interaction between adjuvant therapy and biomarkers, Table 6: Stromal index and patients' outcomes
Figure S1 from A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Topkas Eleni , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Simpson Fiona , Endo-Munoz Liliana , Saunders Nicholas A.
Published: April 2023

Figure S1. Generation of E2F7 and E2F8 deficient murine keratinocytes and the validation of E2F1 levels in E2F1KO mice.
Supplementary Figure 1 from Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Authors: Vardi Anna , Agathangelidis Andreas , Stalika Evangelia , Karypidou Maria , Siorenta Alexandra , Anagnostopoulos Achilles , Rosenquist Richard , Hadzidimitriou Anastasia , Ghia Paolo , Sutton Lesley-Ann , Stamatopoulos Kostas
Published: April 2023

Vardi et al. TCRs in CLL.
Supplementary Figure legends from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure legends. Supplementary Figure legends
Supplementary Table S3 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Table S3. Multivariate analysis of microRNAs signature in relation to relapse-free survival and overall survival in the testing and independent cohorts of triple negative breast cancer patients
Supplementary Figures Legends from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Figures Legends. Supplementary Figures S1-S3 Legends
Supplementary Figure S1 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Figure S1. Circulating microRNA differentially expressed in the training cohort
Supplemental Figure 3 from SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
Authors: Della Corte Carminia Maria , Bellevicine Claudio , Vicidomini Giovanni , Vitagliano Donata , Malapelle Umberto , Accardo Marina , Fabozzi Alessio , Fiorelli Alfonso , Fasano Morena , Papaccio Federica , Martinelli Erika , Troiani Teresa , Troncone Giancarlo , Santini Mario , Bianco Roberto , Ciardiello Fortunato , Morgillo Floriana
Published: April 2023

Graphycal representation of the interplay between Hedgehog and MET pathway.
Figure S1 from PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance
Authors: Pandya Kinnari , Wyatt Debra , Gallagher Brian , Shah Deep , Baker Andrew , Bloodworth Jeffrey , Zlobin Andrei , Pannuti Antonio , Green Andrew , Ellis Ian O. , Filipovic Aleksandra , Sagert Jason , Rana Ajay , Albain Kathy S. , Miele Lucio , Denning Mitchell F. , Osipo Clodia
Published: April 2023

A. Jagged-1 is required for trastuzumab-induced increase of Notch gene targets (Deltex1, Hey1, and Notch4) as measured by RT-PCR in HCC1954 cells. B. Proliferation of HCC1954 cells requires Jagged-1 expression.
Supplemental Figure 1 from SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
Authors: Della Corte Carminia Maria , Bellevicine Claudio , Vicidomini Giovanni , Vitagliano Donata , Malapelle Umberto , Accardo Marina , Fabozzi Alessio , Fiorelli Alfonso , Fasano Morena , Papaccio Federica , Martinelli Erika , Troiani Teresa , Troncone Giancarlo , Santini Mario , Bianco Roberto , Ciardiello Fortunato , Morgillo Floriana
Published: April 2023

Western blot analysis of protein levels and phosphorylated forms of MET, EGFR, MAPK, AKT, GLI1 and beta actin in protein lysates from tumors harvested from nude mice treated with the indicated drugs.
Supplementary Table 1 from FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
Authors: Miller Barry W. , Przepiorka Donna , de Claro R. Angelo , Lee Kyung , Nie Lei , Simpson Natalie , Gudi Ramadevi , Saber Haleh , Shord Stacy , Bullock Julie , Marathe Dhananjay , Mehrotra Nitin , Hsieh Li Shan , Ghosh Debasis , Brown Janice , Kane Robert C. , Justice Robert , Kaminskas Edvardas , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplementary Table 1: Preferred Terms included in grouped terms
supplemental Table 1 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

supplemental Table 1. A list of primers used in the quantitative real-time PCR in this study.
Supplemental Figure 5 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

Supplemental Figure 5. AR-V7 enhances AR transactivation in ENZ-R cells.
Supplemental Figure 2 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

Supplemental Figure 2. AR and mutation F876S status in ENZ-R LNCaP cells and xenografts.
Supplementary Figure S3 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Signaling consequences of treatment with trastuzumab, lapatinib and their combination in HER2-positive colorectal and gastric cancer cells: Duplicate bots for HER receptors.
Supplementary Table S3 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Table S3: In-vivo dual blockade in the subrenal xenograft model. (A) Primary endpoint: tumor volume comparisons among 4 treatment groups: no treatment (NT), gemcitabine 100mg/kg twice weekly, erlotinib 50mg/kg/d, or erlotinib 50mg/kg/d plus BYL-719 25mg/kg/d (ERL+ BYL) (n=90), with t- statistics, P-value and 95% confidence interval around parameter estimate. (B) Secondary endpoint: kidney weight (n=90). All statistics were calculated by two-way ANOVA adjusted by experiments (SAS 9.2). *P<0.05
Supplementary Table 1. from Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Authors: Gebhardt Christoffer , Sevko Alexandra , Jiang Huanhuan , Lichtenberger Ramtin , Reith Maike , Tarnanidis Kathrin , Holland-Letz Tim , Umansky Ludmila , Beckhove Philipp , Sucker Antje , Schadendorf Dirk , Utikal Jochen , Umansky Viktor
Published: April 2023

Multivariate logistic regression analysis of all possible predictive markers for response to Ipilimumab
Supplementary Table 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

FACS and immunohistochemistry analysis of BCMab1 immunoreactivity to human cell lines and normal human tissues.
Supplementary Figure 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Deletion of Integrin α3 in T24 or HCV29 cells by TALEN.
Figure S3 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Figure S3. p53 proficiency is required to induce apoptosis in CRC cell lines and tumors upon anti MEK- and mTOR-inhibition
Figure S2 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Figure S2. Immunohistochemistry of p53 in tumors from CRC patients treated with MEK- plus PI3K-inhibitors
Figure S1 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Authors: García-García Celina , Rivas Martín A. , Ibrahim Yasir H. , Calvo María Teresa , Gris-Oliver Albert , Rodríguez Olga , Grueso Judit , Antón Pilar , Guzmán Marta , Aura Claudia , Nuciforo Paolo , Jessen Katti , Argilés Guillem , Dienstmann Rodrigo , Bertotti Andrea , Trusolino Livio , Matito Judit , Vivancos Ana , Chicote Irene , Palmer Héctor G. , Tabernero Josep , Scaltriti Maurizio , Baselga José , Serra Violeta
Published: April 2023

Figure S1. MEK- and mTOR-inhibition induces cell cycle arrest and apoptosis in CRC cell lines
Supplementary Figure S1 from Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
Authors: Dowsett Mitch , Sestak Ivana , Buus Richard , Lopez-Knowles Elena , Mallon Elizabeth , Howell Anthony , Forbes John F. , Buzdar Aman , Cuzick Jack
Published: April 2023

Supplementary Figure S1: Consort diagram to show the derivation of this cohort from the whole ATAC trial population.
Supplementary Figure S1 from Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Authors: Strekalova Elena , Malin Dmitry , Good David M. , Cryns Vincent L.
Published: April 2023

Supplementary Figure S1. Methionine restriction inhibits cell proliferation.
supplementary figure legends from Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Authors: Varna Mariana , Gapihan Guillaume , Feugeas Jean-Paul , Ratajczak Philippe , Tan Sophie , Ferreira Irmine , Leboeuf Christophe , Setterblad Niclas , Duval Arnaud , Verine Jérôme , Germain Stéphane , Mongiat-Artus Pierre , Janin Anne , Bousquet Guilhem
Published: April 2023

supplementary figure legends
Supplementary Figure S4 from Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Authors: Kerr Martin , Scott Helen E. , Groselj Blaz , Stratford Michael R.L. , Karaszi Katalin , Sharma Naomi L. , Kiltie Anne E.
Published: April 2023

Supplementary Figure S4. Clonogenic plating efficiency of HUVECs in the presence of gemcitabine.
Figure 1, Figure 2, Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 from First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Authors: Meulendijks Didier , Jacob Wolfgang , Martinez-Garcia Maria , Taus Alvaro , Lolkema Martijn P. , Voest Emile E. , Langenberg Marlies H.G. , Fleitas Kanonnikoff Tania , Cervantes Andres , De Jonge Maja J. , Sleijfer Stefan , Soerensen Morten Mau , Thomas Marlene , Ceppi Maurizio , Meneses-Lorente Georgina , James Ian , Adessi Celine , Michielin Francesca , Abiraj Keelara , Bossenmaier Birgit , Schellens Jan H.M. , Weisser Martin , Lassen Ulrik N.
Published: April 2023

Figure 1 Mean ({plus minus}SD) serum lumretuzumab profiles following multiple ascending doses from 100 mg up to 2000 mg Figure 2 Percentage change in standardized uptake value maximum from baseline as assessed by FDG-PET at (a) Cycle 1 Day 14 and (b) Cycle 4 Day 14 Table 1 Summary of baseline and change in HER3 expression measured by IHC in skin and tumor biopsy samples pre and post treatment with lumretuzumab Table 2 Summary of change in expression of HER3, HER2, EGFR and cMET in fresh tumor biopsies compared to primary archival samples Table 3 Peripheral blood immunophenotyping (T, B and NK cells and NK subsets) from patients dosed with 2000 mg lumretuzumab Table 4 Ex-vivo activation potential of peripheral NK lymphocytes for all patients at ba seline and following exposure to lumretuzumab in the 2000 mg dose cohort Table 5 Summary of tumor immune effector cell infiltration Table 6 Tumor response to treatment (RECIST)